Previous studies have shown that knocking-down Fli-1 leads to marked growth inhibition and death in erythroleukemic cells, indicating a possible use of Fli-1 as a therapeutic target to induce tumor suppression [18–20]. Here, FLI1 is linked to neoplasm.